Treatment of prostate cancer

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 2, 1999, Pages 93-102

  Henry, R Y ^a   O'Mahony, D ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL STIMULATING AGENT; ESTRAMUSTINE; ESTROGEN; ETOPOSIDE; GONADORELIN DERIVATIVE; LIAROZOLE; MITOXANTRONE; VINBLASTINE;

AGE; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CHEMOPROPHYLAXIS; DIET; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE THERAPY; HEREDITY; HORMONAL THERAPY; HUMAN; MALE; MEDICAL DECISION MAKING; PROGNOSIS; PROSTATE CANCER; REVIEW; SOCIAL CLASS;

COMBINED MODALITY THERAPY; FORECASTING; HORMONES; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0032978085     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00207.x     Document Type: Review

References (50)

1. Whittemore AS. (1994) Trends in cancer incidence and mortality. Prostate cancer. Cancer Survey, 19/20, 309-322.
2. Jensen OM, Esteve J, Moller H, Renard H, Miller H. (1990) Cancer in the European Community and its member states. The European Journal of Cancer, 26, 1167-1256.
3. Fitzpatrick P, Corcoran N, Fitzpatrick JM. (1998) Prostate cancer: how aware is the public? The British Journal of Urology, 82, 43-48.
4. Johnson Z, Lyons R. (1991) Socioeconomic factors and mortality in small areas. The Irish Medical Journal, 86, 60-62.
5. Fair WR, Fleshner NE, Heston W. (1997) Cancer of the prostate: a nutritional disease? Urology, 50(6), 840-848.
6. Clark LC, Dalkin B, Krongrad A, et al. (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. The British Journal of Urology, 81, 730-734.
7. Whittemore AS, Kolonel LN, Wu AH, et al. (1995) Prostate cancer in blacks, whites and Asians in the United States and Canada. The Journal of National Cancer Institute, 87, 652-661.
8. Carter BS, Steinberg GD, Beaty TH, Childs B, Walsh PC. (1991) Familial risk factors for prostate cancer. Cancer Survey, 11, 5-13.
9. Optenberg SA, Clark JY, Brawer MK, et al. (1997) Development of a decision-making tool to predict risk of prostate cancer: the cander of the prostate risk index (CAPRI) test. Urology, 50, 665-672.
10. Mettlin CJ, Black B, Lee F, et al. (1993) Workgroup 2. Screening and detection: reference range/clinical issues of PSA. Cancer, 71, 2679-2680.
11. Catalona WJ, Smith DS, Ratliff TL, Basler JW. (1993) Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. The Journal of the American Medical Association, 270, 948-954.
12. Harvei S, Tretli S, Langmark F. (1996) Cancer of the prostate in Norway 1957-91, a descriptive study. The European Journal of Cancer, 32A, 111-117.
13. Partin AW, Oesterling JE. (1994) The clinical usefulness of prostatic specific antigen: update. Journal of Urology, 152, 1358-1368.
14. Babaian RJ, Pritsche HA, Zhang Z, Zhang KH, Madyastha KR, Barnhill SD. (1998) Evaluation of ProstAsure index in the detection of prostate cancer; a preliminary report. Urology, 51, 132-136.
15. Franks LM. (1997) Prostatic cancer: future prospects for diagnosis and screening. The British Journal of Urology, 79(Suppl. 1), 107-108.
16. Witherspoon LR. (1997) Early detection of cancer relapse after prostatectomy using very sensitive prostatic specific antigen measurements. The British Journal of Urology, 79(Suppl. 1), 82-86.
17. Beduschi MC, Oesterling JE. (1998) Percent free prostatespecific antigen: the next frontier in prostate-specific antigen testing. Urology, 51(Suppl. 5A), 98-108.
18. Armstrong JG. (1998) The diagnosis and management of prostate cancer. The Irish Medical Times, May 1, 34-35.
19. Fernandes ET, Sundaram CP, Long R, Soltani M, Ercole CJ. (1997) Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer? The British Journal of Urology, 79, 615-617.
20. Denmeade SR, Isaacs JT. (1997) Prostate cancer: where are we and where are we going? The British Journal of Urology, 79(Suppl. 1), 2-7.
21. Onel E, Hamond C, Wasson JH, et al. (1998) Assessment of the feasibility and impact of shared decision making in prostate cancer. Urology, 51, 63-66.
22. Adolfsson J, Steineck G, Hedlund PO. (1997) Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology, 59, 722-726.
23. Feneley MR, Gillatt DA, Hehir M, Kirby RS. (1996) A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome. The British Journal of Urology, 78, 911-920.
24. Austenfeld MS, Davis BE. (1990) New concepts in the treatment of stage Dl adenocarcinoma of the prostate. The Urology Clinic of North America, 17, 867-884.
25. Huggins C, Hodges CV. (1941) The effect of castration of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research, I, 293-297.
26. Herr HW. (1997) Quality of life in prostate cancer patients. Ça: a Cancer Journal for Clinicians, 47, 207-217.
27. Richie JP. (1997) Stage Dl prostate cancer: Delayed androgen deprivation. Urology, 50(6), 838-839.
28. Newling DW. (1997) The palliative therapy of advanced prostate cancer, with particular reference to the results of recent European clinical trials. British Journal of Urology, 79(Suppl. 1), 72-81.
29. The Medical Research Council prostate cancer working party investigators group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. British Journal of Urology, 79, 235-246.
30. Byar DP. (1973) The Veterans Administration Co-operative Urological Research Groups studies of cancer of the prostate. Cancer, 32, 1126-1130.
31. Robinson MRG, Smith PH, Richards B, Ncwling DWW, de Pauw M, Sylvester R. (1995) The final analysis of the EORTC genito-urinary tract cancer co-operative group phase 3 clinical trial (protocol 30805) comparing orchidectomy plus Cyproterone acetate and low dose Stilboestrol in the management of metastatic carcinoma of the prostate. European Urology, 28, 272-283.
32. Bishop MC. (1996) Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. The British Journal of Urology, 78, 921-927.
33. Furr BJ, Casodex (IG 176334). (1989) A new, pure, peripherally selective anti-androgen; preclinical studies. Hormonal Research, 32(Suppl. 1), 69-76.
34. Parmar H, Philips RH, Lightman SL, Edwards L, Allen L, Serially AV. (1985) Randomized controlled study of orchidectomy versus long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet, 2, 1201-1205.
35. Scher H, Kelly WK. (1993) Flutamide withdrawal syndrome; its impact of clinical trial in prostate cancer. Clinical Oncology, 11,1566-1572.
36. Dimopoulos MA, Panopoulos C, Bamia C, et al. (1997) Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology, 50, 754-758.
37. Lotan R. (1986) Mechanisms of action of retinoids. Cancer Bulletin, 38, 113-116.
38. Van Ginckel R, De Coster R, Wouters W, et al. (1990) Antitumoral effects of R075251: on the growth of transplantable R3:327 prostatic adenocarcinoma in rats. Prostate, 16, 313-323.
39. Debruyne FJ, Murray R, Fradet Y, et ni. (1998) Liarozole: a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Urology, 52, 72-81.
40. Scardino PT, Weaver R, Hudson MA. (1992) Early detection of prostate cancer. Human Pathology, 23, 211-222.
41. Murphy GP, Kenny GM, Ragde H, et al. (1998) Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology, 51(Suppl. 5A), 89-97.
42. Steam ME, McGarvey T. (1992) Prostate cancer: therapeutics, diagnostic and basic studies. Lab Investigations, 67, 540-552.
43. Dannull J, Belldegrun AS. (1997) Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Britisli Journal of Urology, 79(Suppl. 1), 97-103.
44. Vukanovic J, Isaacs JT. (1995) Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Research, 55, 3517-3520.
45. Martikainen P, Kyprianou N, Tucker RW, Isaacs JT. (1991) Programmed death of non-proliferating androgen independent prostatic cancer cells. Cancer Research, 51, 4693-4700.
46. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. (1994) The role of calcium, pH and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Research, 54, 6167-6175.
47. Morales A, Johnston B, Emerson L, Heaton JWP. (1997) Intralesional administration of biological response modifiers in the treatment of localized cancer of the prostate: a feasibility study. Urology, 50, 495-502.
48. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. (1974) Steroid 5 alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science, 186, 1213-1215.
49. Gormley GJ, Stoner E, Bruskewitz RC, et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. The New England Journal of Medicine, 327,1185-1191.
50. Allerton J, Seay T, Optenberg S, et al. (1998) Army and air force leadership in the Prostate Cancer Prevention Trial. Urology, 51(Suppl. 4A), 64-66.